CA2025634A1 - Peptides comprenant des epitopes ctl de proteines de hiv et leur utilisation - Google Patents

Peptides comprenant des epitopes ctl de proteines de hiv et leur utilisation

Info

Publication number: CA2025634A1
Authority: CA; Canada
Prior art keywords: peptide fragment; animal; ctl; cells; hiv
Prior art date: 1989-09-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002025634A

Other languages

English (en)

Inventor

Thomas Fuerst

Scott Koenig

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

US Department of Health and Human Services

Original Assignee

MOLECULAR VACCINES Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-19

Filing date

1990-09-18

Publication date

1991-03-20

1990-09-18 Application filed by MOLECULAR VACCINES Inc filed Critical MOLECULAR VACCINES Inc

1991-03-20 Publication of CA2025634A1 publication Critical patent/CA2025634A1/fr

Status Abandoned legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims description 24
102000004169 proteins and genes Human genes 0.000 title claims description 23
108090000765 processed proteins & peptides Proteins 0.000 title description 43
102000004196 processed proteins & peptides Human genes 0.000 title description 9
102000007079 Peptide Fragments Human genes 0.000 claims abstract description 63
108010033276 Peptide Fragments Proteins 0.000 claims abstract description 63
241001465754 Metazoa Species 0.000 claims abstract description 32
241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 17
102100034353 Integrase Human genes 0.000 claims abstract description 16
108010078428 env Gene Products Proteins 0.000 claims abstract description 16
101710192141 Protein Nef Proteins 0.000 claims abstract description 15
101710177291 Gag polyprotein Proteins 0.000 claims abstract description 13
101710125418 Major capsid protein Proteins 0.000 claims abstract description 13
208000015181 infectious disease Diseases 0.000 claims abstract description 10
210000004027 cell Anatomy 0.000 claims description 33
150000001413 amino acids Chemical class 0.000 claims description 18
238000000034 method Methods 0.000 claims description 12
230000004044 response Effects 0.000 claims description 11
210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 10
230000003190 augmentative effect Effects 0.000 claims description 9
125000000539 amino acid group Chemical group 0.000 claims description 8
238000003556 assay Methods 0.000 claims description 8
230000008569 process Effects 0.000 claims description 8
-1 or E)(T Inorganic materials 0.000 claims description 5
239000012634 fragment Substances 0.000 claims description 4
230000009089 cytolysis Effects 0.000 claims 3
230000001939 inductive effect Effects 0.000 claims 3
210000005259 peripheral blood Anatomy 0.000 claims 1
239000011886 peripheral blood Substances 0.000 claims 1
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 abstract description 2
230000024932 T cell mediated immunity Effects 0.000 abstract 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 71
235000018102 proteins Nutrition 0.000 description 21
229940024606 amino acid Drugs 0.000 description 14
235000001014 amino acid Nutrition 0.000 description 14
239000002253 acid Substances 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 4
241000700605 Viruses Species 0.000 description 4
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
102000006601 Thymidine Kinase Human genes 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
241000700618 Vaccinia virus Species 0.000 description 3
206010046865 Vaccinia virus infection Diseases 0.000 description 3
229910052804 chromium Inorganic materials 0.000 description 3
239000011651 chromium Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
239000002609 medium Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
208000007089 vaccinia Diseases 0.000 description 3
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
239000012636 effector Substances 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000010931 gold Substances 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000010354 integration Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000013598 vector Substances 0.000 description 2
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
108010055167 CD59 Antigens Proteins 0.000 description 1
102100022002 CD59 glycoprotein Human genes 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
241001669573 Galeorhinus galeus Species 0.000 description 1
229940033330 HIV vaccine Drugs 0.000 description 1
241000282412 Homo Species 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
101710149951 Protein Tat Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
241000011102 Thera Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
229940037003 alum Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000007402 cytotoxic response Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005065 mining Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
108700004028 nef Genes Proteins 0.000 description 1
101150023385 nef gene Proteins 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
210000002975 pon Anatomy 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA002025634A 1989-09-19 1990-09-18 Peptides comprenant des epitopes ctl de proteines de hiv et leur utilisation Abandoned CA2025634A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40959689A	1989-09-19	1989-09-19
US409,596		1989-09-19

Publications (1)

Publication Number	Publication Date
CA2025634A1 true CA2025634A1 (fr)	1991-03-20

Family

ID=23621182

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002025634A Abandoned CA2025634A1 (fr)	1989-09-19	1990-09-18	Peptides comprenant des epitopes ctl de proteines de hiv et leur utilisation

Country Status (4)

Country	Link
EP (1)	EP0491844A4 (fr)
JP (1)	JPH05502442A (fr)
CA (1)	CA2025634A1 (fr)
WO (1)	WO1991004051A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8423659D0 (en)	1984-09-19	1984-10-24	Pasteur Institut	Cloned dna sequences
US7232654B1 (en)	1983-09-15	2007-06-19	Institut Pasteur	DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1)
US7205102B1 (en)	1983-09-15	2007-04-17	Institut Pasteur	Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA
GB8429099D0 (en)	1984-11-16	1984-12-27	Pasteur Institut	Closed dna sequences
US5980900A (en) *	1984-10-18	1999-11-09	Institut Pasteur And Centre National De La Recherche Scientifique	Amino acid DNA sequences related to genomic RNA of human immunodeficiency virus (HIV-1)
US7045130B1 (en)	1984-10-18	2006-05-16	Institut Pasteur	Antibodies against antigens of human immunodeficiency virus (HIV-1)
US5705612A (en)	1984-10-18	1998-01-06	Institut Pasteur And Centre National De La Recherche Scientifique	NEF peptide encoded by human immunodefiency virus type 1 (HIV-1)
US6894152B1 (en)	1984-11-16	2005-05-17	Institut Pasteur	Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA
US6210873B1 (en)	1987-08-28	2001-04-03	Board Of Regents, The University Of Texas System	Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US5128319A (en)	1987-08-28	1992-07-07	Board Of Regents, The University Of Texas System	Prophylaxis and therapy of acquired immunodeficiency syndrome
US5993819A (en) *	1987-09-08	1999-11-30	Duke University	Synthetic vaccine for protection against human immunodeficiency virus infection
US5221610A (en) *	1988-05-26	1993-06-22	Institut Pasteur	Diagnostic method and composition for early detection of HIV infection
EP0521220A1 (fr) *	1991-06-14	1993-01-07	Institut Pasteur	Actinomycétale immunogène recombinant
EP0671947B1 (fr) *	1991-12-02	2000-03-08	The Board Of Regents, The University Of Texas System	Compositions pour declencher des reactions de lymphocytes t cytotoxiques contre des virus
WO1993019775A1 (fr) *	1992-03-31	1993-10-14	Medimmune, Inc.	Administration de liposomes contenant des peptides ou des proteines comportant des determinants antigeniques de ctl de proteines vih
US5603933A (en) *	1993-08-31	1997-02-18	Board Of Regents, The University Of Texas	CD4 peptides for binding to viral envelope proteins
DE4405810A1 (de)	1994-02-23	1995-08-24	Behringwerke Ag	Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
JP2001502315A (ja) *	1996-10-10	2001-02-20	プローブ・インターナショナル	ウイルス感染を処置するための組成物および方法
AU784679B2 (en)	1999-12-23	2006-05-25	International Aids Vaccine Initiative	Improvements in or relating to immune responses to HIV
AU785143B2 (en)	2000-02-04	2006-10-05	Beth Israel Deaconess Medical Center	Human immunodeficiency virus vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3787002T2 (de) *	1986-12-30	1993-11-25	Us Health	Synthetische Peptide, die zelluläre Immunität gegen den AIDS-Virus und dessen Proteine erzeugen.
AU2914889A (en) *	1987-08-28	1989-04-17	Board Of Regents, The University Of Texas System	Prophylaxis and therapy of acquired immunodeficiency syndrome

1990
- 1990-09-18 CA CA002025634A patent/CA2025634A1/fr not_active Abandoned
- 1990-09-19 EP EP19900914632 patent/EP0491844A4/en not_active Withdrawn
- 1990-09-19 JP JP2513793A patent/JPH05502442A/ja active Pending
- 1990-09-19 WO PCT/US1990/005343 patent/WO1991004051A1/fr not_active Application Discontinuation

Also Published As

Publication number	Publication date
JPH05502442A (ja)	1993-04-28
EP0491844A4 (en)	1993-02-17
EP0491844A1 (fr)	1992-07-01
WO1991004051A1 (fr)	1991-04-04

Legal Events

Date	Code	Title	Description
1996-03-18	FZDE	Discontinued

Publication	Publication Date	Title
CA2025634A1 (fr)	1991-03-20	Peptides comprenant des epitopes ctl de proteines de hiv et leur utilisation
Orentas et al.	1990	Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine
Tomiyama et al.	1997	Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B* 3501 molecules that are associated with the accelerated progression of AIDS.
Takahashi et al.	1989	A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160
Walker et al.	1989	Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.
US6656471B1 (en)	2003-12-02	HIV-specific T-cell induction
McMichael et al.	1986	HLA B37 determines an influenza A virus nucleoprotein epitope recognized by cytotoxic T lymphocytes.
KR100235849B1 (ko)	1999-12-15	HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
Newman et al.	1997	Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations
Sipsas et al.	1997	Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1.
Ikuta et al.	1989	Expression of human immunodeficiency virus type 1 (HIV-1) gag antigens on the surface of a cell line persistently infected with HIV-1 that highly expresses HIV-1 antigens
Bourgault et al.	1994	Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG-or NEF-specific cytotoxic T lymphocytes by lipopeptides.
JP2569185B2 (ja)	1997-01-08	抗ｈｉｖ応答を喚起する合成抗原
Achour et al.	1990	HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.
ES2140380T5 (es)	2005-03-16	Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas.
Yamamoto et al.	1990	Studies of cloned simian immunodeficiency virus-specific T lymphocytes. gag-specific cytotoxic T lymphocytes exhibit a restricted epitope specificity.
Dadaglio et al.	1991	Epitope recognition of conserved HIV envelope sequences by human cytotoxic T lymphocytes.
AU675204B2 (en)	1997-01-30	Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
AU632683B2 (en)	1993-01-07	Peptides stimulating cytotoxic t cells immune to hiv rt
Van Binnendijk et al.	1993	Human HLA class I-and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein
KR19990044093A (ko)	1999-06-25	다수-서브타입 ｆｉｖ 백신
De Groot et al.	1991	Human immunodeficiency virus reverse transcriptase T helper epitopes identified in mice and humans: correlation with a cytotoxic T cell epitope
US20070172930A1 (en)	2007-07-26	process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype isolates, their genes and modifications and derivatives thereof
US5346989A (en)	1994-09-13	Peptides for use in induction of T cell activation against HIV-1
Matsuura et al.	1991	Purification and characterization of human immunodeficiency virus type 1 nef gene product expressed by a recombinant baculovirus